Forte Biosciences (FBRX) Preferred Stock Liabilities (2016 - 2020)

Forte Biosciences (FBRX) has 5 years of Preferred Stock Liabilities data on file, last reported at $10.5 million in Q1 2020.

• On a quarterly basis, Preferred Stock Liabilities changed 0.0% year-over-year to $10.5 million in Q1 2020; TTM through Mar 2020 was $10.5 million, a 0.0% change from a year earlier, with the FY2019 full-year figure at $10.5 million, up 85.81% from the prior year.
• Preferred Stock Liabilities for Q1 2020 stood at $10.5 million, roughly flat from $10.5 million in the prior quarter.
• Over the last five years, Preferred Stock Liabilities for FBRX reached as high as $131.4 million in Q4 2016 and fell as low as $5.7 million in Q4 2018.
• Historically, Preferred Stock Liabilities has averaged $40.1 million across 5 years, with a median of $10.5 million in 2019.
• Across the five-year window, Preferred Stock Liabilities soared 85.81% in 2019 and changed 0.0% in 2020, its largest moves.
• Year by year, Preferred Stock Liabilities stood at $131.4 million in 2016, then changed by 0.0% to $131.4 million in 2017, then plunged by 95.69% to $5.7 million in 2018, then surged by 85.81% to $10.5 million in 2019, then changed by 0.0% to $10.5 million in 2020.
• Per Business Quant data, the three most recent Preferred Stock Liabilities figures were $10.5 million in Q1 2020, $10.5 million in Q4 2019, and $10.5 million in Q3 2019.